Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial DataMichael J. Haller, Louis H. Philipson, Jerry P. Palmer et al.|Diabetes|2019Cited by 132